A single treatment of a FASN inhibitor or semaglutide - improved the NAFLD activity score, or NAS, (NAS ≥ 1 point, 47% and 56%, respectively).

FORMA’s FASN Inhibitor FT-4101 Significantly Reduced Hepatic De Novo Lipogenesis in Healthy Adult Subjects - Phase 1 data presented in a poster session at AASLD’s The Liver Meeting® 2019 - ...

Sagimet Biosciences cleared an IND for TVB-3567, a FASN inhibitor for acne, with Phase 1 trials planned for 2025. Quiver AI Summary Sagimet Biosciences Inc. announced the clearance of its ...

Home News GlobeNewswire Bluejay Therapeutics Reports First Preclinical Data for Liver-Targeted Fatty Acid Synthase (FASN) Inhibitor BJT-188 Being Investigated for the Treatment of Metabolic ...